NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Required) - October 2025 Deadline
Request Ticket // Limit: 4* (see below) // Tickets Available: 3
Cancer Data Science // Limit: 1 // Tickets Available: 1
Cancer Control Science // Limit: 1 // Tickets Available: 0
S. Yeo (Public Health - Competitive Resubmission)
Molecular Precision/Cancer Prevention // Limit: 1 // Tickets Available: 1
Other Cancer Research // Limit: 1 // Tickets Available: 1
Number of Applications
Applicant organizations may submit more than one application, provided that each application is scientifically distinct, and each is from a different candidate.
NIH will not accept duplicate or highly overlapping applications under review at the same time per NIH Grants Policy Statement Section 2.3.7.4 Submission of Resubmission Application. An individual may not have two or more competing NIH career development applications pending review concurrently. In addition, NIH will not accept:
- A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
- A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.
- An application that has substantial overlap with another application pending appeal of initial peer review. (See NIH Grants Policy Statement 2.3.9.4 Similar, Essentially Identical, or Identical Applications).
Each eligible institution (defined as having a unique UEI number or NIH IPF number) may submit up to a combined total of four applications (one in Cancer Data Science, one in Cancer Control Science, one in Molecular/Precision Cancer Prevention, and one in Other Cancer Research) to any companion NOFO or any combination of companion NOFOs (PAR-23-286, PAR-23-287, and/or PAR-23-288).
Scientific Areas
- (A) Cancer Data Science: For the purposes of this K99/R00 award, cancer data science is defined as an interdisciplinary field of inquiry in which quantitative and analytical approaches, processes, and systems are both developed and used to extract knowledge and insights from increasingly large and/or complex sets of data. This includes cancer-focused data integration and visualization, systems biology, artificial intelligence, machine learning, informatics, genomics, precision oncology, and developing analytics for epidemiological or biostatistical studies.
- (B) Cancer Control Science: For the purposes of this K99/R00 award, cancer control science is defined as basic and applied research in the behavioral, social, and population sciences to create or enhance interventions that, independently or in combination with biomedical approaches reduce cancer risk, incidence, morbidity, and mortality, and improve quality of life. This includes research in epidemiology, behavioral sciences, health services, surveillance, cancer survivorship, and healthcare policy.
- (C) Molecular/Precision Cancer Prevention: For the purpose of this K99/R00 award, early translational research in cancer prevention is defined as basic research to understand mechanisms of cancer formation, development and progression of cancer precursors, and to translate basic biological knowledge into novel human interventions and human-centered adaption of current interventions with the potential to reduce cancer risk, incidence, and mortality, and improve quality of life. This includes but is not limited to research in molecular and systems biology, diagnostics, vaccine and drug development, pharmacology, and biomedical engineering.
- (D) Other Cancer Research: For the purposes of this K99/R00 award, "Other Cancer Research" includes all scientific fields supported by the NCI that are not included in (A), (B) or (C). Applicants proposing research in (D) "Other Cancer Research" may apply only if it is reasonable to expect their candidates to transition to independence with an abbreviated period of mentored research training beyond their original doctoral degrees."